Cancer Communications
indexed by SCI
BMC

Letter to the Editor
Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
Wen Cai, Biao Cai, Juan Zhou, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue & Jiwei Huang
Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Rd., Pudong District, Shanghai, 200127, P. R. China
[Abstract] None
Cancer Communications   Epub date: 10/11/2019   doi:10.1186/s40880-019-0405-5
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Wen Cai, Biao Cai, Juan Zhou, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue & Jiwei Huang. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. Cancer Commun (Lond). 2019, 39:56. doi:10.1186/s40880-019-0405-5


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by BioMed Central

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China